BACKGROUND: PDE1 (phosphodiesterase type 1) hydrolyzes cyclic adenosine and guanosine monophosphate. ITI-214 is a highly selective PDE1 inhibitor that induces arterial vasodilation and positive inotropy in larger mammals. Here, we assessed pharmacokinetics, hemodynamics, and tolerability of single-dose ITI-214 in humans with stable heart failure with reduced ejection fraction. METHODS: Patients with heart failure with reduced ejection fraction were randomized 3:1 to 10, 30, or 90 mg ITI-214 single oral dose or placebo (n=9/group). Vital signs and electrocardiography were monitored predose to 5 hours postdose and transthoracic echoDoppler cardiography predose and 2-hours postdose. RESULTS: Patient age averaged 54 years; 42% female, and 60% Black. Mean systolic blood pressure decreased 3 to 8 mm Hg (P<0.001) and heart rate increased 5 to 9 bpm (P≤0.001 for 10, 30 mg doses, RM-ANCOVA). After 4 hours, neither blood pressure or heart rate significantly differed among cohorts (supine or standing). ITI-214 increased mean left ventricular power index, a relatively load-insensitive inotropic index, by 0.143 Watts/mL2·104 (P=0.03, a +41% rise; 5-71 CI) and cardiac output by 0.83 L/min (P=0.002, +31%, 13-49 CI) both at the 30 mg dose. Systemic vascular resistance declined with 30 mg (-564 dynes·s/cm-5, P<0.001) and 90 mg (-370, P=0.016). Diastolic changes were minimal, and no parameters were significantly altered with placebo. ITI-214 was well-tolerated. Five patients had mild-moderate hypotension or orthostatic hypotension recorded adverse events. There were no significant changes in arrhythmia outcome and no serious adverse events. CONCLUSIONS: Single-dose ITI-214 is well-tolerated and confers inodilator effects in humans with heart failure with reduced ejection fraction. Further investigations of its therapeutic utility are warranted. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03387215.
BACKGROUND: PDE1 (phosphodiesterase type 1) hydrolyzes cyclic adenosine and guanosine monophosphate. ITI-214 is a highly selective PDE1 inhibitor that induces arterial vasodilation and positive inotropy in larger mammals. Here, we assessed pharmacokinetics, hemodynamics, and tolerability of single-dose ITI-214 in humans with stable heart failure with reduced ejection fraction. METHODS: Patients with heart failure with reduced ejection fraction were randomized 3:1 to 10, 30, or 90 mg ITI-214 single oral dose or placebo (n=9/group). Vital signs and electrocardiography were monitored predose to 5 hours postdose and transthoracic echoDoppler cardiography predose and 2-hours postdose. RESULTS: Patient age averaged 54 years; 42% female, and 60% Black. Mean systolic blood pressure decreased 3 to 8 mm Hg (P<0.001) and heart rate increased 5 to 9 bpm (P≤0.001 for 10, 30 mg doses, RM-ANCOVA). After 4 hours, neither blood pressure or heart rate significantly differed among cohorts (supine or standing). ITI-214 increased mean left ventricular power index, a relatively load-insensitive inotropic index, by 0.143 Watts/mL2·104 (P=0.03, a +41% rise; 5-71 CI) and cardiac output by 0.83 L/min (P=0.002, +31%, 13-49 CI) both at the 30 mg dose. Systemic vascular resistance declined with 30 mg (-564 dynes·s/cm-5, P<0.001) and 90 mg (-370, P=0.016). Diastolic changes were minimal, and no parameters were significantly altered with placebo. ITI-214 was well-tolerated. Five patients had mild-moderate hypotension or orthostatic hypotension recorded adverse events. There were no significant changes in arrhythmia outcome and no serious adverse events. CONCLUSIONS: Single-dose ITI-214 is well-tolerated and confers inodilator effects in humans with heart failure with reduced ejection fraction. Further investigations of its therapeutic utility are warranted. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03387215.
Authors: J Yu; S L Wolda; A L Frazier; V A Florio; T J Martins; P B Snyder; E A Harris; K N McCaw; C A Farrell; B Steiner; J K Bentley; J A Beavo; K Ferguson; R Gelinas Journal: Cell Signal Date: 1997-11 Impact factor: 4.315
Authors: Sanja Beca; Faiyaz Ahmad; Weixing Shen; Jie Liu; Samy Makary; Nazari Polidovitch; Junhui Sun; Steven Hockman; Youn Wook Chung; Matthew Movsesian; Elizabeth Murphy; Vincent Manganiello; Peter H Backx Journal: Circ Res Date: 2012-11-19 Impact factor: 17.367
Authors: Fiona Murray; Hemal H Patel; Ryan Y S Suda; Shen Zhang; Patricia A Thistlethwaite; Jason X-J Yuan; Paul A Insel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-09-15 Impact factor: 5.464
Authors: Yevgeniya O Lukyanenko; Antoine Younes; Alexey E Lyashkov; Kirill V Tarasov; Daniel R Riordon; Joonho Lee; Syevda G Sirenko; Evgeny Kobrinsky; Bruce Ziman; Yelena S Tarasova; Magdalena Juhaszova; Steven J Sollott; David R Graham; Edward G Lakatta Journal: J Mol Cell Cardiol Date: 2016-06-27 Impact factor: 5.000
Authors: Fabrice Vandeput; Sharon L Wolda; Judith Krall; Ryan Hambleton; Lothar Uher; Kim N McCaw; Przemyslaw B Radwanski; Vincent Florio; Matthew A Movsesian Journal: J Biol Chem Date: 2007-08-28 Impact factor: 5.157
Authors: Sahib S Khalsa; Teresa A Victor; Rayus Kuplicki; Hung-Wen Yeh; Kimberly E Vanover; Martin P Paulus; Robert E Davis Journal: Neuropsychopharmacology Date: 2022-04-29 Impact factor: 8.294
Authors: Grace K Muller; Joy Song; Vivek Jani; Yuejin Wu; Ting Liu; William P D Jeffreys; Brian O'Rourke; Mark E Anderson; David A Kass Journal: Circ Res Date: 2021-09-15 Impact factor: 23.213
Authors: Keivan Golshiri; Ehsan Ataei Ataabadi; Annika A Jüttner; Gretchen L Snyder; Robert E Davis; Amy Lin; Lei Zhang; René de Vries; Ingrid M Garrelds; Frank P J Leijten; A H Jan Danser; Anton J M Roks Journal: Front Pharmacol Date: 2022-01-31 Impact factor: 5.810
Authors: Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt Journal: Cardiovasc Res Date: 2022-07-20 Impact factor: 13.081